Skip to content

Miltenyi Biotech

Together with Miltenyi Biotech, the LIT is developing a cGMP-compliant, semi-automated manufacturing platform for the generation of CD22/CD19-bispecific CD8+ Tscm cells. The cellular product developed will be tested in patients with relapsed or refractory aggressive B-cell non-Hodgkin lymphoma.

 

Poseida Therapeutics

Together with Poseida Therapeutics, the LIT is developing a manufacturing platform for the generation of NY-ESO-1-TCR-redirected Tscm cells, functionally empowered through the overexpression of human miR-155 SNP rs377265631. The cellular product developed will be tested in patients with relapsed or refractory sarcoma.